Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have sh...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fang, Bank, Thomas, Malnassy, Gregory, Arteaga, Maribel, Shang, Na, Dalheim, Annika, Ding, Xianzhong, Cotler, Scott J., Denning, Mitchell F., Nishimura, Michael I., Breslin, Peter, Qiu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983153/
https://www.ncbi.nlm.nih.gov/pubmed/29881824
http://dx.doi.org/10.1002/hep4.1181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983153/
https://www.ncbi.nlm.nih.gov/pubmed/29881824
http://dx.doi.org/10.1002/hep4.1181

Ejemplares similares